IgA Nephropathy

Patients with IgA nephropathy experienced nearly 30% proteinuria reduction after 6 months of treatment with SGLT2 inhibitors.

Findings showed the probability of achieving total remission was significantly greater in the corticosteroid pulse group compared to the oral corticosteroid group.

Interim results from the phase 3 APPLAUSE-IgAN study showed a statistically significant reduction in proteinuria among patients treated with iptacopan compared to placebo.

Positive findings from NefIgArd demonstrated budesonide’s ability to modulate the intestinal immune network responsible for IgA production.

Phase 3 data show a significant clinical profile associated with durable reductions in IgA nephropathy biomarkers among patients treated with Nefecon.

Discussing the key differences in the results of ISCHEMIA and ISCHEMIA-CKD, which examined whether the use of invasive or conservative strategies was more effective for patients with ischemic heart disease.

Topline data from Rigel Pharmaceuticals’ proof-of-concept Phase 2 study of fostamatinib in patients with IgA nephropathy, or Berger’s disease, were announced today.